Form 4: VolitionRx Director Ethel Rubin Receives Stock Award in Lieu of Cash Compensation

Director Ethel Rubin of VolitionRx Ltd. received 8,648 restricted stock units (RSUs) in lieu of cash compensation, vesting over several dates.

Summary

• Ethel Rubin, a director at VolitionRx Ltd., was granted 8,648 restricted stock units (RSUs) on December 1, 2024.
• These RSUs were awarded in place of cash compensation that was due to her.
• The RSUs vest in three installments of 2,883 units, 2,883 units, and 2,882 units on December 1, 2024, January 1, 2025, and February 1, 2025, respectively.
• A final vesting installment occurs on July 1, 2025, subject to continued service.
• Upon vesting, Rubin will receive common stock equal to the number of vested RSUs.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of stock-based compensation for a director, which is generally viewed positively as it aligns interests with shareholders. There are no negative implications.

Positives

• The award of RSUs aligns the director's interests with those of the shareholders.
• The vesting schedule encourages continued service and commitment from the director.

Risks

• The value of the RSUs is subject to the volatility of the company's stock price.
• The director must remain in service to fully vest the RSUs.

Future Outlook

The director will receive shares of common stock upon the vesting of the RSUs, subject to continued service.

Industry Context

The use of stock-based compensation is a common practice for incentivizing directors and aligning their interests with shareholders in the biotechnology industry.

Comparison to Industry Standards

• Stock-based compensation is a standard practice for directors in publicly traded companies, particularly in the biotech sector.
• The vesting schedule is typical, with multiple tranches over a period of time to encourage long-term commitment.
• Companies like Exact Sciences (EXAS) and Guardant Health (GH) also use stock options and RSUs as part of their director compensation packages.

Stakeholder Impact

• Shareholders may view the stock award positively as it aligns the director's interests with the company's performance.
• The award does not have a direct impact on employees, customers, suppliers, or creditors.

Next Steps

• The director will continue to vest in the RSUs over the next several months.
• The director will receive shares of common stock upon vesting.

Key Dates

Keywords

restricted stock units, RSUs, stock compensation, director compensation, insider trading, VolitionRx, VNRX, Ethel Rubin